Clene Inc. (CLNN) is a Consumer Defensive · Packaged Foods company listed on NASDAQ. Price $4.40 (+6.02%), Market cap $0.09B, 52-week low–high $2.37 ~ $12.50.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic
Financial statements, price targets, institutional (13F) holdings and related news for Clene Inc. are updated in real time on BlackAll Trade.
Clene Inc. trades at $4.40 (+6.02%). Real-time quotes and charts are available on BlackAll Trade.
Clene Inc. has a market cap of about $0.09B.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug can